Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8324607 | 0.89 | MTNR1A (0.71) | SMN1; SMN2ALDH1A1MTNR1AMTNR1BHTT | |
| Tert-Butyl Formate SCHEMBL28033419 | 0.89 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1MTNR1AMTNR1BHTT | |
| SCHEMBL5205624 | 0.86 | NPC1 (0.69) | MTNR1AMTNR1BHTTHPGDACHE | |
| SCHEMBL3188745 | 0.84 | ENPP3 (0.69) | MTNR1AMTNR1BHTTHPGDNPC1 | |
| SCHEMBL1724757 | 0.84 | MTNR1A (0.70) | ALDH1A1MTNR1AMTNR1BPOLB | |
| SCHEMBL30518933 | 0.83 | MTNR1A (0.64) | SMN1; SMN2ALDH1A1MTNR1AMTNR1BHTT | |
| SCHEMBL2446469 | 0.83 | ALOX15 (0.59) | MTNR1AMTNR1BHTTHPGDACHE | |
| SCHEMBL13144615 | 0.83 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1HTTNPSR1POLB | |
| SCHEMBL19494423 | 0.82 | MTNR1A (0.64) | SMN1; SMN2MTNR1AMTNR1BHTTHPGD | |
| SCHEMBL5223237 | 0.82 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1MTNR1AMTNR1BHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | claimed |
| CN-118666840-A | Design synthesis and application of spiro [ pyrrolidine-3, 3 '-quinoline ] -2,2' -diketopiperidine carboxamide compound | 西南大学 | 2024-09-20 | — | — | CN | disclosed |
| EP-3127912-B1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | UNIV ZHEJIANG (CN) | 2021-04-21 | — | — | EP | disclosed |
| CN-104945470-B | Tripeptide epoxy ketone compound constructed by heterocycle, preparation and application | 浙江大学 | 2020-08-11 | — | — | CN | disclosed |
| US-9856288-B2 | Tripeptide epoxyketone compound constructed by heterocycle and preparation method and use thereof | ZHEJIANG UNIVERSITY (CN) | 2018-01-02 | — | — | US | disclosed |
| EP-3127912-A1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | Zhejiang University (CN) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022250-A1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA , CHINESE ACADEMY OF SCIENCES (CN) | 2017-01-26 | — | — | US | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0717739-A1 | BICYCLIC AROMATIC COMPOUNDS AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007274-A1 | BICYCLIC AROMATIC COMPOUNDS AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022250-A1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | VIP, DNPEP, PREP | SMN1; SMN2 4538/4885ALDH1A1 3368/4885MTNR1A 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.